Drug resistance in schistosomes

Area of Science:

• Biochemistry
• Parasitology
• Drug Discovery

Background:

• Drug resistance in schistosomes is a significant concern, particularly for hycanthone and oxamniquine.
• Praziquantel remains a widely effective treatment with no documented resistance cases.
• Understanding resistance mechanisms is crucial for developing new anti-schistosome therapies.

Purpose of the Study:

• To investigate the biochemical basis of drug resistance in schistosomes.
• To elucidate the mechanism of action for hycanthone and oxamniquine.
• To identify potential targets for novel drug design against schistosomiasis.

Main Methods:

• Utilized genetically characterized strains of Schistosoma mansoni (resistant and sensitive).
• Performed biochemical analyses to study drug activation pathways.
• Investigated the role of enzymatic esterification in drug metabolism.

Main Results:

• Hycanthone and oxamniquine require enzymatic esterification for activation into an electrophilic moiety.
• This activated form alkylates parasite DNA and macromolecules.
• Resistance is caused by the absence of a specific drug-activating enzyme in resistant schistosomes and mammalian hosts.

Conclusions:

• The drug-activating enzyme is essential for hycanthone and oxamniquine efficacy.
• Loss of this enzyme confers resistance in schistosomes.
• Studying this enzyme could guide the development of new anti-schistosome drugs and improve understanding of parasite metabolism.